TRX518: Phase I data

Data from 28 evaluable patients with melanoma or other advanced refractory solid tumors in the open-label, U.S. Phase I TRX518-001 trial showed that a single dose of 0.0001-8 mg/kg IV TRX518 led to 4 ...